Blueprint Medicines Corporation
BPMC · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Market Cap | $5,629 | $5,547 | $5,863 | $6,862 |
| - Cash | $122 | $102 | $89 | $55 |
| + Debt | $123 | $469 | $471 | $740 |
| Enterprise Value | $5,630 | $5,914 | $6,245 | $7,548 |
| Revenue | $149 | $146 | $128 | $138 |
| % Growth | 2.1% | 14.2% | -7.2% | – |
| Gross Profit | $147 | $139 | $126 | $127 |
| % Margin | 98.1% | 94.9% | 98.5% | 91.9% |
| EBITDA | -$41 | -$27 | -$33 | -$29 |
| % Margin | -27.5% | -18.5% | -26% | -21.3% |
| Net Income | $0 | -$50 | -$56 | -$50 |
| % Margin | 0.3% | -34.1% | -43.9% | -36.2% |
| EPS Diluted | 0.01 | -0.79 | -0.89 | -0.8 |
| % Growth | 101.3% | 11.2% | -11.2% | – |
| Operating Cash Flow | -$54 | -$29 | -$14 | -$48 |
| Capital Expenditures | -$2 | -$1 | -$0 | -$3 |
| Free Cash Flow | -$56 | -$30 | -$14 | -$51 |